AFS-13-269-E March 21, 2013

Exemption No. 10690B Regulatory Docket No. FAA-2013-0034

Stacey Bechdolt, Esq. Director, Safety & Technical Affairs Regional Airline Association 2025 M Street, NW., Suite 800 Washington, DC 20036

Mr. Douglas Mullen

Assistant General Counsel

Airlines for America 1301 Pennsylvania Avenue, NW, Suite 1100 Washington, DC 20004

Mr. George Paul

Director of Technical Services

National Air Carrier Association 1000 Wilson Boulevard, Suite 1700 Arlington, VA 22209

Dear Ms. Bechdolt:

This letter is to inform you that we have granted your petition to amend Exemption No. 10690, as amended. It explains the basis for our decision, describes its effect, and lists

the revised conditions and limitations.

The Basis for Our Decision

By letter dated March 4, 2013, you petitioned the Federal Aviation Adm inistration (FAA) on behalf of Regional Airline Association (RAA) for an amendment to Exemption No. 10690, as amended. That exemption from § 121.803(c)(3) and Appendix A of part 121 of Title 14, Code of Federal Regulations (14 CFR) provi des relief from the requirement to include2

Atropine in an Emergency Medical Kit (EMK). The amendment you request would add Empire Airlines to the list of part 119 certificate holders authorized under this exemption.

In your petition, you indicate that there has been no change in the conditions and reasons relative to public interest and safety that were the basis for granting the original exemption.

The FAA has determined that good cause exists for not publishing a summary of the petition in the Federal Register because delaying action would adversely affect the air carriers due to the imminent effect on operations that would be caused by the Atropine shortage.

In considering this amendment the FAA recognizes that air carriers are coping with a nationwide manufacturing shortage that leaves affected certificate holders without an alternate means to comply. Further, the nationwide shortage is affecting not only EMK suppliers, but also ground-based medical service providers. Therefore, the FAA finds that it is in the public interest to extend this grant of exemption to all part 119 certificate holders authorized to conduct part 121 passenger carrying operations.

Our Decision

Under the authority contained in 49 U.S.C. §§ 40113 and 44701, which the FAA

Adm inistrator has delegated to me, I hereby grant passenger member airlines of Regional Airline Association, Airlines for America, and National Air Carrier Association, and all similarly situated air carriers, an exemption from 14 CFR § 121.803(c)(3) and Appendix A of part 121, to the extent necessary to relieve them from the requirement to carry two single dose ampules of Atropine 5cc injectable, in required on-board EMKs when, due to the nationwide shortage discussed herein, they are unable to procure these items for the kits. This exemption is subject to the following conditions and limitations.

Conditions and Limitations

1. This exem ption applies to the part 119 certificate holders authorized to conduct part 121 passenger carrying operations.

2. A copy of this exemption must be carried on board each aircraft operating with emergency medical kits that do not include Atropine as required by Appendix A of part 121.3

3. As part of the requirement under §119.43(c) to keep each of its employees and other persons used in its operation informed of the provisions of their operations specifications that apply to that employee’s or person’s duties and responsibilities, the certificate holders must inform crewmembers that any emergency medical kits on board the aircraft may not contain Atropine.

4. This exemption may be used for flights conducted outside of the United States.

The Effect of Our Decision

The term ination date of Exemption No. 10690, as amended, remains January 31, 2014, unless sooner superseded or rescinded.

Sincerely,

/s/

John S. Duncan Deputy Director, Flight Standards

Service